Decapeptide-12
Decapeptide-12 is a synthetic skin-brightening peptide that competitively inhibits tyrosinase and reduces melanin synthesis in melanocytes.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Decapeptide-12 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Competitive tyrosinase inhibition reducing melanin synthesis
- Brightens hyperpigmented skin with good tolerability
- Targets melanocyte signaling without cytotoxicity
- Decapeptide-12 is not FDA-approved for human use. Cosmetic ingredient. INCI listed as Decapeptide-12.
Research At a Glance
- Competitive tyrosinase inhibition reducing melanin synthesis
- Brightens hyperpigmented skin with good tolerability
- Targets melanocyte signaling without cytotoxicity
- Suitable for sensitive skin compared to hydroquinone
What is Decapeptide-12?
Tap any underlined term for an instant definition.
Decapeptide-12 is a synthetic ten-amino acid peptide designed as a competitive inhibitor of tyrosinase, the rate-limiting enzyme in melanin synthesis. Its design was based on identifying peptide sequences that bind the copper-containing active site of tyrosinase more effectively than the natural substrate L-DOPA, thereby reducing melanin production without the cytotoxic effects associated with hydroquinone.
What It Is
- A synthetic decapeptide (10 amino acids) targeting the tyrosinase enzyme active site
- Acts as a competitive tyrosinase inhibitor
- INCI name: Decapeptide-12; commercial name: Lumixyl
- Used in skin brightening formulations at very low concentrations (5-10 ppm)
How It Works
- Competes with L-DOPA (the tyrosinase substrate) for binding at the enzyme's copper-containing active site
- Reduces the conversion of L-tyrosine to L-DOPA and L-DOPA to dopaquinone (the first two steps of melanin synthesis)
- Does not affect melanocyte viability, making it mechanistically different from cytotoxic brightening agents
- Example: In primary melanocyte cultures, Decapeptide-12 at 10 ppm reduced melanin content by 35% over 14 days vs vehicle, with no significant effect on cell viability by MTT assay
Key Research Findings
- Tyrosinase inhibition IC50: Approximately 1 nM in cell-free tyrosinase activity assays (using L-DOPA as substrate)
- Comparative study: Decapeptide-12 showed equivalent melanin reduction to hydroquinone 4% in melanocyte culture with significantly better cell viability outcomes
- Clinical study: A double-blind randomized controlled trial in 60 patients with facial hyperpigmentation showed 30% reduction in melanin index at 8 weeks with 1.0% Lumixyl (containing Decapeptide-12) vs placebo
Dosing From the Literature
- Topical: 5-10 ppm active peptide in formulation
- Applied once or twice daily to hyperpigmented areas
Storage and Handling
- Lyophilised: 2-8 degrees C; stable 24 months
- In formulation: stable at pH 5-7
- Avoid strong UV exposure which can degrade the peptide
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Decapeptide-12. See all Skin & Anti-Aging peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Applied topically to hyperpigmented areas once or twice daily.
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.